Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alvotech - Ordinary Shares
(NQ:
ALVO
)
11.08
-0.27 (-2.38%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Alvotech - Ordinary Shares
< Previous
1
2
3
4
5
Next >
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Alvotech, and Sanmina and Encourages Investors to Contact the Firm
July 31, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Alvotech Completes $100 Million Convertible Bond Private Placement
July 31, 2023
From
Alvotech
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm
July 26, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership
July 24, 2023
From
Alvotech
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm
July 21, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm
July 16, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm
July 10, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm
July 05, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Ascendis, Alvotech, Shift4, and Waldencast and Encourages Investors to Contact the Firm
June 30, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02
June 28, 2023
From
Alvotech
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Zai Lab, Hayward, Ascendis, and Alvotech and Encourages Investors to Contact the Firm
June 25, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating C3.ai, Ascendis, Alvotech, and Shift4 and Encourages Investors to Contact the Firm
June 19, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®
June 12, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®
June 12, 2023
From
Alvotech
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating RH, Alvotech, and TriplePoint and Encourages Investors to Contact the Firm
June 04, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Alvotech Investors With Losses to Inquire About Securities Class Action Investigation - ALVO, ALVOW
June 03, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Exposures
Product Safety
Alvotech to Participate in Jefferies Healthcare Conference
May 31, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech and Advanz Pharma extend strategic partnership to commercialize five proposed biosimilars in Europe
May 24, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech Reports Financial Results for First three Months of 2023 and Provides Business Update
May 19, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech to Participate in Morgan Stanley Annual Sustainable Finance Summit
May 17, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech Issues Annual Equality Report Covering 2022
May 15, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech enters into commercialization agreement with Polifarma for proposed biosimilar to Eylea® (aflibercept)
May 10, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech Initiates Confirmatory Patient Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
May 04, 2023
From
Alvotech
Via
GlobeNewswire
ALVOTECH ALERT: Bragar Eagel & Squire, P.C. is Investigating Alvotech on Behalf of Alvotech Stockholders and Encourages Investors to Contact the Firm
May 03, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
ALVO, ALVOW INVESTOR NEWS: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Alvotech Investors With Losses in Excess of $100K to Inquire About Securities Class Action Investigation – ALVOW
May 03, 2023
From
The Rosen Law Firm, P.A.
Via
Business Wire
Alvotech to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 18, 2023 and Host Conference Call on May 19, 2023 at 8:00 am ET
May 03, 2023
From
Alvotech
Via
GlobeNewswire
ALVOTECH ALERT: Bragar Eagel & Squire, P.C. is Investigating Alvotech on Behalf of Alvotech Stockholders and Encourages Investors to Contact the Firm
April 19, 2023
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Sarah Tanksley Joins Board of Directors for Alvotech hf. and Sandra Casaca Appointed Chief Quality Officer
April 19, 2023
From
Alvotech
Via
GlobeNewswire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Alvotech and Encourages Investors with Losses to Contact the Firm
April 19, 2023
From
The Schall Law Firm
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Alvotech (ALVO) on Behalf of Investors
April 19, 2023
From
Law Offices of Howard G. Smith
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.